HOME >> MEDICINE >> NEWS
University of Kentucky Markey Cancer Center Researchers Awarded Grant To Fight Leukemia Recurrence

LEXINGTON, KY (Sept. 1, 1998) - Imagine sparing leukemia patients a second round of chemotherapy. That's what University of Kentucky Markey Cancer Center researchers hope to do with a three-year, $321,459 grant from the Leukemia Society of America. Craig Jordan, Ph.D., assistant professor of medicine, UK College of Medicine, and John Yanelli, Ph.D., associate professor of internal medicine, UK College of Medicine, will use the money to design gene therapy-based treatments to help leukemia patients avoid recurrence of the disease.

Despite recent advances in treatment, cancer recurrence remains a long-term problem. Cancer cells often travel throughout the body, thus, some malignant cells may escape chemical or surgical removal. To tackle this problem, Jordan and Yanelli have devised a method to prevent relapse by allowing the patient's immune system to "mop up" residual tumor cells in the bloodstream. It's based on a promising technique called immunotherapy. Used to treat other cancer types, immunotherapy targets immune cells to attack a disease.

"We're going to educate the immune system in the lab," Jordan said. "We've invented a new technology to genetically change the tumor cell."

The researchers plan to extract tumor cells from a patient, culture them, and then using a virus as a transfer agent, will introduce human genes into the cell. The genes are selected for their ability to generate an immune response toward cancer cells.

The cultured cells then would be crippled by radiation - the cells will not die, but will lose the ability to reproduce. After patients complete a standard regime of chemotherapy, the irradiated tumor cells will be reinfused into their body.

Researchers hope the genetically engineered cells will rev up the patient's immune system to seek and destroy any remaining cancer cells.

The procedure should be almost completely nontoxic, Jordan said. It would eliminate a second round of chemotherapy for patients, reduce
'"/>

Contact: krcumb0@pop.uky.edu
krcumb0@pop.uky.edu
(606) 323-6363
University of Kentucky Medical Center
1-Sep-1998


Page: 1 2

Related medicine news :

1. Indiana University researchers closer to helping hearing-impaired using stem cells
2. Boston University team finds link between high cholesterol and better cognitive performance
3. University seeks recruits for arthritis study
4. University of Manchester awarded 826k for brain science and mental health research
5. $4 million grant boosts University of Michigan campaign for a new childrens hospital
6. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
7. Next generation body scanner launched by the University of Manchester
8. University of Washington joins new Autism Treatment Network to provide better medical services
9. Binghamton University launches microelectronics research center
10. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
11. RelayHealth selected by Columbia University to link doctors and patients online

Post Your Comments:
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... is available in Spanish . ... neglected diseases, it goes by the name of the 10/90 ... devoted to conditions that accounted for 90 per cent of ... that the Drugs for Neglected Diseases initiative (DNDi) came into ... organization has been granted the BBVA Foundation Frontiers of Knowledge ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s indoor air ... kit at an exceptional price. The 5-2-1 Compressor Saver (also ... unit during start up, saving wear and tear on the ... out. , The 5-2-1 Compressor Saver works by ... power to start and drastically reduces the rush of heat ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3
(Date:6/19/2013)... DIEGO , June 19, 2013   Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain.  This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...
(Date:6/19/2013)... -- Today leading web researchers Change Sciences Group ( ... sites for usability, engagement, and conversion. The rankings are ... compares how people experience sites with competitors and with ... top three performers are easier to use, more engaging ... have usability problems, lack aspects of design that compel ...
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
Cached News: